McClung MR, et al. - Given that over 12 months, romosozumab increased bone formation and decreased bone resorption, resulting in increased bone mineral density (BMD) in postmenopausal women with low BMD, the researchers intended to assess 24 months of treatment with romosozumab, discontinuation of romosozumab, alendronate followed by romosozumab, and romosozumab followed by denosumab. They enrolled postmenopausal women aged 55 to 85 years with a lumbar spine (LS), total hip (TH), or femoral neck T-score ≤–2.0 and ≥–3.5. Results of this study suggested that treatment effects of romosozumab were reversible upon discontinuation and further augmented by denosumab.